What is KYBELLA ?

KYBELLA (deoxycholic acid) injection is the first and only FDA-approved injectable treatment that is used in adults to improve the appearance and profile of moderate to severe fat below the chin (submental fat), also called, “double chin.” It is not known if KYBELLA is safe and effective in children less than 18 years of age. It is not known if KYBELLA is safe and effective for use outside of the submental area.

How does KYBELLA work?

The active ingredient in KYBELLA is deoxycholic acid, a naturally-occurring molecule in the body that aids in the breakdown and absorption of dietary fat.

When injected into the fat beneath your chin, KYBELLA causes the destruction of fat cells. Once destroyed, those cells cannot store or accumulate fat.

Is KYBELLA right for me?

Only you and your doctor can decide if KYBELLA is right for you. If you’re bothered by submental fullness, or double chin, ask your doctor about KYBELLA .

Will I experience any side effects?

The safety profile of KYBELLA is well characterized. The most common side effects are swelling, bruising, pain, numbness, redness and areas of hardness around the treatment area. KYBELLA can cause serious side effects, including trouble swallowing and nerve injury in the jaw that can cause an uneven smile or facial muscle weakness. These are not all of the possible side effects of KYBELLA . Call your healthcare provider for medical advice about side effects.

How long will the results last?

When injected into the fat under your chin, KYBELLA causes the destruction of fat cells. Once destroyed, those cells cannot store or accumulate fat. After the aesthetic response is achieved, retreatment with KYBELLA is not expected.2

How many treatments will I need?

You and your doctor will customize your KYBELLA treatment regimen, including how many treatments you need, based on your desired chin profile. Many patients experience visible results in 2 to 4 treatment sessions. During these sessions, your HCP will administer KYBELLA into the fat under your chin using multiple injections. Up to 6 treatment sessions may be administered spaced no less than one month apart.

  • In clinical studies, results for KYBELLA – treated patients who had a ≥1-grade composite improvement were 8% (1 treatment), 28% (2 treatments), 43% (3 treatments), 55% (4 treatments), 66% (5 treatments) and 72% (6 treatments)
  • In clinical studies, results for KYBELLA -treated patients who had a ≥2-grade composite improvement were 0% (1 treatment), .2% (2 treatments), .8% (3 treatments), 3.5% (4 treatments), 3.9% (5 treatments) and 15% (6 treatments)
  • 59% of subjects in the clinical trials received all 6 treatments

female2-front-kybella

female2-side-kybella

male1-front-kybella

male1-side-kybella

female1-front-kybella

female1-side-kybella

Important Safety Information

KYBELLA should only be administered by a trained healthcare professional.

KYBELLA is contraindicated in the presence of infection at the injection sites.

Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness, were reported in 4% of subjects in the clinical trials. KYBELLA should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve; all cases resolved spontaneously (range 1-298 days, median 44 days).

Dysphagia occurred in 2% of subjects in the clinical trials in the setting of administration site reactions, e.g., pain, swelling, and induration of the submental area; all cases of dysphagia spontaneously resolved (range 1-81 days, median 3 days). Avoid use of KYBELLA in these patients as current or prior history of dysphagia may exacerbate the condition.

In clinical trials, 72% of subjects treated with KYBELLA experienced hematoma/bruising. KYBELLA should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet or anticoagulant therapy as excessive bleeding or bruising in the treatment area may occur.

To avoid the potential of tissue damage, KYBELLA should not be injected into or in close proximity (1-1.5 cm) to salivary glands, lymph nodes and muscles.

The most commonly reported adverse reactions in the pivotal clinical trials were: injection site edema/swelling, hematoma/bruising, pain, numbness, erythema, and induration.

Schedule a consultation for Kybella® today. During a consultation, patients meet with their aesthetician and staff to discuss all options in more detail. Patients may ask questions about desired outcome as well as view before and after photos of similar procedures.